Summary
The study objective was to obtain detailed information on the bioavailability and pharmacokinetics of the new fixed combination of delapril and indapamide following single and multiple dosing. For this reason, the study was performed in two parts, separated by a medication-free period of at least 7 days. In the single dose part, one tablet, containing 30 mg delapril and 2.5 mg indapamide, was administered to 12 male volunteers; in the multiple dose part, the volunteers received one tablet of the test preparation, once daily over 7 days. Following single and on the last day of the multiple dosing regimen, blood samples were withdrawn and serum concentrations of delapril and its metabolites M1, M2 and M3 and whole blood concentrations of indapamide were quantified by means of HPLC methods. In addition, urine samples were collected following single and multiple dosing for evaluation of the cumulative amount of delapril and its metabolites M1–M3 excreted in urine.
For the area under the curve, calculated from time 0 to infinity (AUC(0–∞)) the study revealed, following single dosing, mean values of delapril and its metabolites M1, M2 and M3 of 281, 2178, 739 and 716 h.ng/ml, respectively; for indapamide the mean value was 1597 h.ng/ml. The corresponding mean values found after multiple dose administration were 272, 2071, 857 and 598 h.ng/ml for delapril and its metabolites, respectively and 1536 h.ng/ml for indapamide. Evaluation of the cumulative amount of delapril and its metabolites M1–M3 excreted in urine (Ae) demonstrated mean values following single dosing (observation period 36 h) of 705, 4521, 454 and 4203 μg, respectively; the corresponding values after multiple dose administration (observation period 24 h) of the test preparation were 655, 4679, 469 and 4801 μg, respectively.
The most important pharmacokinetic parameters AUC(0−∞) and Ae were statistically compared by analysis of variance (ANOVA) and 90% confidence intervals were calculated.
It may be concluded from the results of this study, that the bioavailability and pharmacokinetic parameters of the test preparation after single dosing and after multiple doses correspond well.
The undesired side effects observed are known to occur after administration of the test preparation. The occurrence was a little more frequent after multiple dose application in comparison with the single dose administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Miyake A., Itoh K., Oka Y. (1986): Design and synthesis of N-[N-[(S)-1-ethoxy-carbonyl-3-phenylpropyl]-l-alanyl]-N-(indan-2-yl)glycine (CV3317), a new potent angiotensin converting enzyme inhibitor. Chem. Pharm. Bull., 34, 2852–2858.
Captopril: worldwide clinical experience (1982): Br. J. Clin. Pharmacol., 14 (Suppl. 2), 69S-252S.
Romankiewicz J.A., Brogden R.N., Heel R.C., Speight T.M., Avery G.S. (1983): Captopril: an update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs, 25, 6–40.
Gavras H., Brunner H.R., Turini G.A., et al. (1978): Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N. Engl. J. Med., 298, 991–995.
Ondetti M.A., Rubin B., Cushman D.W. (1977): Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science, 196, 441–444.
Gavras H., Biollaz J., Waeber B., Brunner H.R., Gavras I., Davis R.O. (1981): Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor ‘MK-421’. Lancet, ii, 543–546.
Cody R.J. (1984): Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. Drugs, 28, 144–169.
Sharpe D.N., Murphy J., Coxon R., Hannan S.F. (1984): Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study Circulation, 70, 271–278.
Shionoiri H., Yasuda G., Ikeda A., Ohta E., Miyajima E., Kaneko Y. (1987): Pharmacokinetics and depressor effect of delapril in patients with essential hypertension. Clin. Pharm. Ther., 41, 74–79.
Inada Y., Tanabe M., Shibouta Y., Kawazoe K., Nishikawa K., Kikuchi S. (1986): Antihypertensive action of a non-sulphydryl angiotensin converting enzyme inhibitor (CV-3317) in various hypertensive models. Jpn. J. Pharmacol., 42, 1–8.
Inada Y., Therashita Z.I., Imura Y., Tanabe M., Nishikawa K., Kikucchi S. (1986): Inhibition of angiotensin converting enzyme by CV-3317, a non-sulfhydryl compound. Jpn. J. Pharmacol., 42, 99–108.
Clinical overview on CV-3317 (Delapril). Summary of studies in Japan. Takeda Chemical Industries Ltd, January 1989.
Rutsaert R., Fernandes M. (1983): Indapamide. In: Scriabine A. (ed) New Drugs Annual: Cardiovascular Drugs. New York, Raven Press.
Chaffman M., Heel R.C., Brogden R.N., Speight T.M., Avery G.S. (1984): Indapamide: A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs, 28, 189–235.
Caruso F.S., Szabadi R.R., Vukovich R.A. (1983): Pharmacokinetics and clinical pharmacology of indapamide. Am. Heart J., 106 (Suppl), 212–220.
Witchitz S., Giudichelli J.F., El Guedri H., Kamoun A., Chiche P. (1974): Effects diuretiques et anti-hypertenseurs de l’indapamide: comparaison avec le furosemide. Therapie, 29, 109–118.
Campbell D.B., Moore R.A. (1981): The pharmacology and clinical pharmacology of indapamide. Postgrad. Med. J., 57 (Suppl. 2), 7–17.
Choi R.L., Rosenberg M., Grebow P.E., Huntley T.E. (1987): High-performance liquid chromatographic analysis of indapamide (RHC 2555) in urine, plasma and blood. J. Chromatogr., 230, 181–187.
Pabst G., Jaeger H. (1990): Review of methods and criteria for the evaluation of bioequivalence studies. Eur. J. Clin. Pharmacol., 38, 5–10.
Evaluation of the Bioavailability and Pharmacokinetics of the Combination Preparation Delapril/Indapamide and the Mono-Preparation Delapril and Indapamide in Nine (9) Healthy Male Volunteers (L.A.B. Report 89054) LAB GmbH & Co, D-7910 Neu-Ulm, Germany, May 1991.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hutt, V., Pabst, G., Dilger, C. et al. Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers. Eur. J. Drug Metab. Pharmacokinet. 19, 59–69 (1994). https://doi.org/10.1007/BF03188824
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03188824